These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34558200)

  • 1. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
    Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
    Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
    Perera V; Wang Z; Lubin S; Ueno T; Shiozaki T; Chen W; Xu X; Seiffert D; DeSouza M; Murthy B
    Sci Rep; 2022 Mar; 12(1):5165. PubMed ID: 35338177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
    Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milvexian for the Prevention of Venous Thromboembolism.
    Weitz JI; Strony J; Ageno W; Gailani D; Hylek EM; Lassen MR; Mahaffey KW; Notani RS; Roberts R; Segers A; Raskob GE;
    N Engl J Med; 2021 Dec; 385(23):2161-2172. PubMed ID: 34780683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.
    Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
    Cardiol Ther; 2022 Sep; 11(3):407-419. PubMed ID: 35641780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
    Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
    J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
    Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
    Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.
    Perera V; Abelian G; Luettgen J; Aronson R; Li D; Wang Z; Zhang L; Lubin S; Merali S; Murthy B
    Sci Rep; 2024 Jul; 14(1):16591. PubMed ID: 39025971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
    Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
    Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
    Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
    Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
    Dilger AK; Pabbisetty KB; Corte JR; De Lucca I; Fang T; Yang W; Pinto DJP; Wang Y; Zhu Y; Mathur A; Li J; Hou X; Smith D; Sun D; Zhang H; Krishnananthan S; Wu DR; Myers JE; Sheriff S; Rossi KA; Chacko S; Zheng JJ; Galella MA; Ziemba T; Dierks EA; Bozarth JM; Wu Y; Crain E; Wong PC; Luettgen JM; Wexler RR; Ewing WR
    J Med Chem; 2022 Feb; 65(3):1770-1785. PubMed ID: 34494428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
    van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.
    Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
    Sci Rep; 2022 Dec; 12(1):22239. PubMed ID: 36564395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
    Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics and safety of the novel C-X-C chemokine receptor 3 antagonist ACT-777991: Results from the first-in-human study in healthy adults.
    Boof ML; Géhin M; Voors-Pette C; Hsin CH; Sippel V; Strasser DS; Dingemanse J
    Br J Clin Pharmacol; 2024 Feb; 90(2):588-599. PubMed ID: 37752659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.